A phase III study to evaluate the efficacy and safety of GSK1358820 in subjects with post-stroke upper limb spasticity

Trial Identifier: 207660
Sponsor: GlaxoSmithKline
NCTID:: NCT03261167
Start Date: August 2017
Primary Completion Date: March 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Aichi, Japan, 465-8620
Japan Aichi, Japan, 490-1405
Japan Chiba, Japan, 279-0021
Japan Chiba, Japan, 277-8567
Japan Fukui, Japan, 910-0067
Japan Fukuoka, Japan, 819-8551
Japan Hiroshima, Japan, 734-8530
Japan Hiroshima, Japan, 720-0825
Japan Hokkaido, Japan, 005-0802
Japan Hyogo, Japan, 651-2181
Japan Ibaraki, Japan, 300-0028
Japan Ibaraki, Japan, 312-0057
Japan Kagoshima, Japan, 890-0067
Japan Kanagawa, Japan, 245-8560
Japan Kanagawa, Japan, 232-0024
Japan Kanagawa, Japan, 227-8518
Japan Kanagawa, Japan, 259-1143
Japan Kochi, Japan, 780-0051
Japan Kumamoto, Japan, 862-0924
Japan Nagano, Japan, 399-6461
Japan Niigata, Japan, 945-8585
Japan Oita, Japan, 870-0862
Japan Okayama, Japan, 703-8265
Japan Osaka, Japan, 570-8507
Japan Osaka, Japan, 580-0032
Japan Osaka, Japan, 538-0044
Japan Saga, Japan, 849-8501
Japan Shizuoka, Japan, 417-0801
Japan Shizuoka, Japan, 433-8511
Japan Tokushima, Japan, 770-8503
Japan Tokyo, Japan, 192-0032
Japan Tokyo, Japan, 102-8798
Japan Tokyo, Japan, 123-0853
Japan Tokyo, Japan, 105-8471
Japan Tokyo, Japan, 201-8601
Japan Tokyo, Japan, 165-8906
Japan Wakayama, Japan, 641-8509
Japan Yamagata, Japan, 992-0057